Research programme: antibacterials - Microbiotix
Alternative Names: 259C; AcrAB-TolC efflux pump inhibitors - Microbiotix; Aminospectinomycins - Microbiotix; AU-FQ hybrids; bIAI compounds; bis-imidazolinylindole compound series; Fatty acid biosynthesis (FAB) pathway inhibitors - Microbiotix; GON X - Microbiotix; Inhibitors of DnaA initiator protein - Microbiotix; Inhibitors of initiation of DNA replication - Microbiotix; Inhibitors of wall teichoic acid (WTA) - Microbiotix; MBX 1158; MBX 1162; MBX 1196; MBX 1337; MBX 1339; MBX 1641; MBX 2319 analogues - Microbiotix; MBX 3132; MBX 3795; MBX 3796; MBX 3797; MBX 4191; MBX-500; Sortase A (SrtA) inhibitors for Gram-positive infections - Microbiotix; SOS induction inhibitors - Microbiotix; Spectinamide antibacterials for MDR/XDR tuberculosis - Microbiotix; Spectinomycin analogues - Microbiotix; T3SS inhibitors; TTSS inhibitors; Tuberculosis therapies - Microbiotix; VAP X- MicrobiotixLatest Information Update: 28 Aug 2024
Price :
$50 *
At a glance
- Originator Microbiotix
- Developer GLSynthesis; Microbiotix
- Class Acetamides; Amidines; Aminocyclitols; Antibacterials; Carboxylic acids; Coumarins; Heterocyclic compounds; Imidazoles; Indoles; Pyrans; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA helicase inhibitors; DNA helicase-primase inhibitors; DNA synthesis inhibitors; DNA-binding protein inhibitors; DNA-directed DNA polymerase inhibitors; Lipoteichoic acid inhibitors; Membrane protein inhibitors; Sortase A inhibitors; Toll-like receptor 5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Gonorrhoea; Gram-negative infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections; Tuberculosis
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Gonorrhoea in USA (PO)
- 28 Aug 2024 No recent reports of development identified for research development in Pseudomonal-infections(Combination therapy, Prevention) in USA
- 25 Aug 2022 Early research in Pseudomonal-infections(Combination therapy, Prevention) is ongoing in USA (CARB-X pipeline, August 2022)